Kathy’s testimonial is another inspirational Obagi Nu Derm® transformation story that we are excited to share with our readers!

Like so many others, Kathy suffered with sun damage that manifested as freckles and sun spots. She wanted to diminish her hyperpigmentation, but wasn’t sure where to start.

Fortunately, her aesthetician introduced her to the Obagi Nu Derm system, and she hasn’t looked back since! During treatment, Kathy’s skin initially looked worse before it looked better, as it needed time to adjust to a new system of products with active ingredients.

However, after a few weeks, Kathy began to see noticeable results* and this motivated her to continue. And we are so glad she did!

Check out her inspirational story with before and after photos:

My name is Kathy and I’m 54 years old. I met my aesthetician, Hillary, in November 2016. She recommended the Obagi Nu Derm system for my hyperpigmentation. As you can see in my before photos, I had freckles, sun spots, and sun damage.

I then started using the products for several months daily. Initially, there was some redness and peeling, and it took several weeks for my skin to adjust. As I adjusted to the products and I started to see results, it motivated me to keep going.

At month 3, I started to use ELASTIderm Eye Cream as well as Sun Shield TINT SPF 50, which I wear every day. At about month 4, I was using the Obagi Nu Derm products as maintenance, and that is what I’ve continued for the last 11 months.”






*Individual results may vary.

The safety and effectiveness of the Obagi Nu-Derm System beyond 24 weeks of use have not been established. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. See below for Important Safety Information about the Obagi Nu-Derm system.


(Contain prescription 4% hydroquinone)


People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.


Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.


Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.

Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.